Erasca (ERAS) Climbs 390% YTD on ‘Best-in-Class' Potential of Cancer Treatment [Yahoo! Finance]
Erasca, Inc. (ERAS)
Company Research
Source: Yahoo! Finance
Erasca has seen its share prices soar by 390 percent year-to-date, as investors sought to increase their exposure in the company amid developments on its treatment candidate for solid tumors. Earlier in the year, Erasca Inc. (NASDAQ:ERAS) expanded its worldwide rights to develop and commercialize its treatment candidate, ERAS-0015—which has a best-in-class potential—to China, Hong Kong, and Macau, sparking revenue growth opportunities in the said areas. Photo by Pietro Jeng on Pexels In addition, it inked a collaboration and supply agreement with Tango Therapeutics Inc. to evaluate the efficacy of ERAS-0015 when combined with the latter's PRMT5 inhibitor, vopimetostat (TNG462). The combination represents a promising opportunity to redefine the standard of care in patients with MTAP-deleted RAS-mutant (MTAPdel RASm) cancers, where treatment options remain limited, Erasca Inc. (NASDAQ:ERAS) said. The company is targeting to report the results of its clinical trial for ERAS-00
Show less
Read more
Impact Snapshot
Event Time:
ERAS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ERAS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ERAS alerts
High impacting Erasca, Inc. news events
Weekly update
A roundup of the hottest topics
ERAS
News
- What's Driving Erasca (ERAS)'s Nearly 355% YTD Return [Yahoo! Finance]Yahoo! Finance
- Erasca (ERAS) Among the Best Performing Stocks of Q1 2026 to Watch for Q2 [Yahoo! Finance]Yahoo! Finance
- Erasca CMO's Direct Stake Hit Zero. Her Options Position Didn't [Yahoo! Finance]Yahoo! Finance
- Assessing Erasca (ERAS) Valuation After ERAS-0015 Licensing Win And Data Anticipation [Yahoo! Finance]Yahoo! Finance
- Erasca (ERAS) Adds 13%; Soars 310% YTD [Yahoo! Finance]Yahoo! Finance
ERAS
Earnings
- 11/12/25 - In-Line
ERAS
Sec Filings
- 4/15/26 - Form 144/A
- 4/15/26 - Form 144
- 4/3/26 - Form 4
- ERAS's page on the SEC website